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We have studied the effect of oxidative stress on pro-
tein synthesis in rat liver. Cumene hydroperoxide (CH)
was used as an oxidant agent. The approach used was to
determine the ribosomal state of aggregation and the
time for assembly and release of polypeptide chains in
the process of protein synthesis in rat liver in vivo. The
results suggest that the elongation step is the most sen-
sitive to CH treatment. The measurement of both car-
bonyl groups content and ADP-ribosylatable elongation
factor 2 (EF-2), the main protein involved in the elonga-
tion step, indicates that under CH treatment EF-2 is
oxidatively modified and a lower amount of active EF-2
is present. These results are corroborated by in vitro
oxidation of EF-2 and could explain for the decline in
the elongation step.
The effect of oxidative stress on protein metabolism have
been reported by various laboratories (1–13). Most of these
studies have focused on protein degradation, the major finding
being that oxidatively modified proteins become susceptible to
proteolytic digestion (2, 4–7, 9–13). With respect to protein
synthesis, the effect of active oxygen species has been less
studied and has been addressed by using oxidizing agents
(14–16). One of such compounds is cumene hydroperoxide
(CH),1 which has been used as an intracellular source of reac-
tive oxygen intermediates (17–22). Besides its damaging effects
such as membrane damage, cell lysis, organ necrosis, tumor
promotion (20), and certain aspects of aging (23), it has been
reported that this compound and/or cytotoxic aldehydes de-
rived from it inhibit protein synthesis in human skin fibro-
blasts (14). These in vitro results were obtained by measuring
the incorporation of radioactive amino acid precursors into
proteins, a methodology which is not suitable when using whole
animal systems because of the difficulty in measuring the
specific activity of the amino acid precursor pool (23). Further-
more, a detailed molecular mechanism of the decline of protein
synthesis caused by the oxidant is not available.
Because of the potential importance of decreased protein
synthesis in structural and functional deterioration of the cell,
the molecular basis for decreased rate of protein synthesis by
CH, and hence by oxidative stress, is of interest, especially
since this decrease may be an important contributor to certain
processes in which free radicals seem to be involved, such as
aging (25).
In order to understand the mechanism underlying the inhi-
bition of protein synthesis by CH, we have studied: 1) which of
the individual steps in polypeptide synthesis is most affected,
and 2) the possible mechanism of how active oxygen species
may interact with the protein synthetic machinery.
The effect of CH on the stages of protein synthesis has been
studied by investigating the ribosome half-transit time (elon-
gation time) required for the synthesis of an average half-
length of a nascent polypeptide chain (26), and the ribosomal
state of aggregation (27, 28), which is reflected by the polyri-
bosomal profiles.
The results show that the CH treatment for 7 days produced
a decrease in the rate of peptide chain elongation along with a
higher state of polyribosome aggregation in rat liver. These
findings suggest that the elongation step is the more sensitive
to CH treatment. The observed decline in the rate of elongation
step seems to be produced by modifications of the EF-2, the
main protein involved in this process.
MATERIALS AND METHODS
Experimental Animals and Treatment—Female Wistar rats, 200 g
body weight, were used in all the experiments. CH (Sigma, 80%) was
dissolved in saline and the solution was sonicated for 5 s at 50 watts.
CH-treated rats received an intraperitoneal injection of CH (35 mg/kg
body weight/day) at 10 a.m. for 7 days. The control group received NaCl
injection. We followed the weight of each animal and found that the rate
of increase was similar for all rats used.
Determination of Liver Polyribosomal Profiles—Liver polyribosomal
profiles were determined basically as described previously (27, 28). A
portion of liver was homogenized in 2 volumes of a media containing 50
mM triethanolamine, 5 mM MgCl2, 25 mM KCl, 0.25 M sucrose (pH 7.3).
The homogenate was centrifuged at 20,000 3 g and 2.3 ml of the
supernatant were mixed with 0.3 ml of 20% sodium deoxycholate and
5.2 ml of 50 mM triethanolamine, 5 mM MgCl2, 25 mM KCl, 2.3 M
sucrose, 7 mM 2-mercaptoethanol (pH 7.3). This mixture was layered
over 3.4 ml of a solution containing 2.3 M sucrose, 50 mM triethanola-
mine, 5 mM MgCl2, 25 mM KCl (pH 7.3), and 0.6 ml of a 105,000 3 g
supernatant obtained by 2 h ultracentrifugation of control liver homo-
genate (1:2) in 50 mM triethanolamine, 5 mM MgCl2, 25 mM KCl, 0.25 M
sucrose (pH 7.3). The preparation was centrifuged for 16 h at 150,000 3
g in the Beckman rotor 65. The pellet was gently suspended in a
medium containing 50 mM triethanolamine, 5 mM MgCl2, 25 mM KCl
(pH 7.3) and centrifuged at 12,000 3 g in a microcentrifuge. The
absorbance of the suspension at 260 nm was monitored and a volume
containing 4 units of OD was layered on 10 ml of a 20–40% linear
sucrose gradient made up in the same buffer. The gradient was centri-
fuged in an SW 40.1 Beckman rotor for 35 min at 35,000 rpm and
pumped from the tube using a gradient unloader (Nycomed Pharma).
The absorbance at 254 nm was continuously recorded using a flow-
through cuvette. A blank obtained by measuring the absorbance at 254
nm of 10 ml of the 20–40% sucrose gradient was subtracted from all
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polyribosomal profiles. The area under the curve in polyribosomal pat-
tern was quantified using a laser computing densitometer.
Measurement of Incorporation of Amino Acid into Liver Protein—The
procedure for the determination of radioactivity in total and nascent
proteins was similar to the one described previously (26, 29) and was as
follows. The animals were anesthetized with pentobarbital (5 mg/100 g
weight). The abdomen of the rat was opened along the ventral midline.
The hepatic portal vein was exposed by gently shifting the intestines
within the abdominal cavity, and an injection of 20 mCi of L-[3,4-
3H]valine in 0.2 ml of NaCl solution was made over a period of 30 s. The
needle was kept in the vein to prevent bleeding. Small liver biopsies
were taken 0.5, 1, 1.5, and 2 min after the completion of the amino acid
administration, taking only two biopsies from each liver (at 0.5 and 1.5
min or at 1 and 2 min). To prevent hemorrhage, liver lobules were
ligated immediately before biopsies were taken. Liver samples were
frozen by aluminum clamps pre-cooled in liquid nitrogen and stored at
this temperature until they were homogenized in 3 volumes of 0.3 M
sucrose. A 1.5-ml portion of the homogenate was diluted with 1.5 ml of
a medium containing 0.1 M Tris/HCl (pH 7.6) and 2 mM magnesium
acetate. The mixture was layered over 1 ml of 0.5 M sucrose containing
1 mM magnesium acetate and centrifuged at 4,000 3 g for 15 min. Two
ml of the supernatant were mixed with 200 ml of 20% sodium deoxy-
cholate. After 30 min at 4 °C, the solution was centrifuged at 8,000 3 g for
15 min. The resulting supernatant was used to estimate the radioactivity
of total liver protein and the ribosomal nascent polypeptide chains.
To measure radioactivity of total liver protein, 0.5 ml of the super-
natant was mixed with 3 ml of 10% trichloroacetic acid. After sediment-
ing at 8,000 3 g for 10 min, the pellet was washed twice with 3 ml of
10% trichloroacetic acid. After the last wash, the pellet was resus-
pended in 3 ml 10% trichloroacetic acid and heated for 30 min at 90 °C.
The precipitate collected by centrifugation was resuspended succes-
sively in 3 ml of ethanol/chloroform/ether (2:2:1, v/v), acetone and ether.
The washed pellet was left at room temperature until the ether had
evaporated. The dry pellet was suspended in 0.5 ml of protosol, allowed
to stand overnight at 60 °C, and after adding 17 ml of acetic acid,
transferred to a vial containing 10 ml of toluene-2,5-diphenyl oxazol
scintillation mixture.
The incorporation of radioactive amino acid into nascent chains was
determined using 1.5 ml of supernatant. This volume was layered over
6 ml of a medium containing 1 M sucrose, 1 mM magnesium acetate, and
1 ml of a 105,000 3 g supernatant obtained by 2 h ultracentrifugation
of control liver homogenate (1:2) in 50 mM triethanolamine, 5 mM
MgCl2, 25 mM KCl, and 0.25 M sucrose (pH 7.3). The mixture was
centrifuged at 28,000 rpm for 14 h in a Beckman 42 Ti rotor at 0 °C. The
pellet was resuspended in 1 ml of distilled water. This suspension was
treated as already described for the determination of radioactivity in
total proteins.
Determination of Radioactivity in Plasma—To confirm that the in-
jection of radioactive valine had been done properly, a sample of blood
was taken from the heart. Aliquots of 10 ml of serum were transferred
to vials containing 10 ml of Formula-989 liquid scintillation mixture
(NEN Research Products) for the determination of radioactivity. An
average of 2,200 cpm was obtained.
Determination of Hepatic Valine-specific Radioactivity—Fifty ml of
homogenates from liver were deproteinized with 1 ml of 20% trichloro-
acetic acid and the precipitate was removed by centrifugation. Aliquots
of the supernatant were transferred to vials containing 10 ml of toluene-
based scintillation mixture for the determination of radioactivity.
Determination of Malonaldehyde (MDA) with Thiobarbituric Ac-
id—A portion of liver tissue was homogenated in 5 volumes of 50 mM
Tris-HCl (pH 7.5), 1 mM EDTA, 20% glycerol, 0.2 mM dithiothreitol and
0.3 mM phenylmethylsulfonyl fluoride. The homogenate was centri-
fuged at 10,000 3 g. The supernatant was centrifuged again at
105,000 3 g. The pellet was gently suspended in homogenization buffer.
The sample (liver microsome suspension or 10,000 3 g supernatant)
was mixed with 2 volumes of cold 10% (w/v) trichloroacetic acid to
precipitate protein. The precipitate was pelleted by centrifugation, and
an aliquot of the supernatant was used for MDA determination (30).
Production of Polyclonal Antibodies against EF-2—A synthetic pep-
tide (H-CGTRFTDTRKDEQGC-NH2) corresponding to a particular re-
gion of EF-2 (Chiron Mimotopes Peptide Systems, Australia) was used
to prepare rabbit polyclonal antibodies against EF-2. The synthetic
peptide was coupled to keyhole limpet hemocyanin using a conjugation
kit of Pierce. The specificity of the polyclonal antibody was tested by
immunostaining of nitrocellulose membranes after electrophoretic
transfer of rat liver homogenates. A Western blot of an SDS-gel elec-
trophoresis of liver homogenate yielded a single band at the expected
molecular mass of 100 kDa.
Quantification of EF-2—Concentration of EF-2 in the cell-free sys-
tems was measured by an enzyme-linked immunoabsorbent assay. A
sample of liver extract was diluted in carbonate-bicarbonate buffer (pH
9.0) (100 mg of protein/ml). The wells of a Nunc microtiter plate were
coated, in triplicate, with 100 ml and incubated overnight at 4 °C.
Unbound sites were blocked with 200 ml of 3% (w/v) bovine serum
albumin-Tween. After rinsing, 100 ml of anti-EF-2 solution diluted
1/100 in phosphate-buffered saline-Tween were added to each well and
incubated for 1 h at room temperature. The plate was then washed as
before and incubated for 1 h at room temperature with a mouse anti-
rabbit Ig-peroxidase. After 1 h of incubation at room temperature, 100
ml of substrate solution (10 mg of 2,29-azino-di-[3-ethylbenzthiazoline
sulfonate(6)] diammonium salt dissolved in 100 ml of citrate buffer (pH
5.8) containing 0.02% hydrogen peroxide) were distributed into each
well. The reaction was left to develop for 60 min at room temperature,
in the dark.
Elongation Factor Assay—A sample of liver was homogenated in 3
volumes of homogenization buffer containing 50 mM Tris-HCl, 1 mM
EDTA, 1 mM dithiothreitol, 50 mM NaCl, 0.25 M sucrose, and 0.2 mM
phenylmethylsulfonyl fluoride. The homogenate was shaken vigorously
in charcoal for 5 min to remove endogenous NAD. Charcoal was re-
moved by centrifugation (15,000 3 g, 20 min) and the supernatant was
centrifuged again (27,000 3 g, 15 min) to remove cellular debris and to
ensure elimination of all charcoal. All operations were performed at
0–4 °C.
The amount of “active” EF-2 was determined in liver extracts as
described previously (31, 32). Briefly, the assay was performed in a final
volume of 500 ml in a buffer of 20 mM Tris-HCl, 50 mM dithiothreitol,
and 1 mM EDTA, containing 10 mg of diphtheria toxin (DT), 0.18 M
histamine, and 0.1 mM [14C]NAD (0.1 mCi). The reaction was started by
mixing in an aliquot of liver extract and the assay mixture was incu-
bated 90 min at 37 °C. The reaction was stopped by adding 1 ml of cold
10% perchloric acid. After centrifugation, the radioactivity incorporated
into the protein pellet was determined as described above.
Determination of Carbonyl Groups of Proteins in Homogenates—
Carbonyl groups were determined by measurement of incorporation of
tritium into proteins after reduction with NaB3[H]4 as described by
Lenz et al. (33).
Determination of Carbonyl Groups of EF-2—A sample of hepatic
105,000 3 g supernatant was labeled with radioactive sodium borohy-
dride (33). After incubation for 30 min at 37 °C, samples were exten-
sively dialyzed in a Microdialyzer system 500 (Pierce) using a 12,000Mr
cut-off dialysis membrane. Polyclonal antibody against EF-2 was incu-
bated with protein A-Sepharose CL-4B (Sigma) for 4 h at 4 °C. The
complex was washed three times in 10 mM Tris-HCl (pH 7.5), 140 mM
NaCl, 1% Triton X-100, 1% deoxycholic acid, and 0.1% SDS (RIPA
buffer). An aliquot of the radiolabeled sample was incubated with the
complex protein A-antibody overnight at 4 °C. The samples were cen-
trifuged in a microcentrifuge and the immunoprecipitate was washed
three times with RIPA buffer. Radioactivity incorporated into EF-2 was
determined using 10 ml of Ready-Protein liquid scintillation mixture
(Beckman Instruments).
“In Vitro” Study of CH Effect on Carbonyl Groups and Ribosylatable
Diphthamide Content of EF-2—Rat liver homogenate (105,000 3 g
supernatant) was treated with 1 mM CH for 90 min. After this, CH and
endogenous NAD were removed by extensive dialysis. Carbonyl group
content of EF-2 was determined using tritiated sodium borohydride
(33). For the measurement of ribosylatable-diphthamide content of
EF-2, the control and oxidized sample were treated with radioactive
NAD plus DT. Radioactivity incorporated into EF-2 was determined as
described above.
RESULTS
Oxidative Effect of CH Treatment on Rat Liver—CH is an
oxidant, which has been used to assess the effects of free
radicals and reactive oxygen intermediates on various biologi-
cal molecules (17–22). In the present study, the oxidative effect
of CH has been determined by measuring MDA and carbonyl
groups content in liver extracts. Aldehydes are always pro-
duced when lipid hydroperoxides break down in biological sys-
tems (29), and MDA is the most abundant individual aldehyde
resulting from lipid peroxidation. Its determination by thiobar-
bituric acid is one of the most common assays in lipid peroxi-
dation studies (30). In addition, the carbonyl groups content in
proteins is used as an index of protein oxidative damage (33).
CH treatment produced a significant increase in MDA of 2.7-
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and 3.4-fold in 10,000 3 g supernatant and microsome fraction,
respectively (Table I). A significant increase of carbonyl groups
content of liver proteins was also found in both subcellular
fractions (Table I).
Effect of CH Treatment on Polypeptide Chain Completion
Time—Polypeptide chain completion time was calculated as-
suming that after injection, the radioactive amino acid will
meet the ribosomes in the middle of the translation of a mRNA
of average size. When a full cycle is completed, the whole
peptide on the ribosomes will be labeled, while the chains that
have been terminated and released will be only half-labeled.
Thus, the ratio between the radioactivity incorporated into
nascent peptides in the polyribosomes (Pn) and that incorpo-
rated into total peptides (Pt) will be reduced by 50%, and the
time required to reduce Pn/Pt from 50 to 25% is taken as the
average polypeptide chain completion time, Tc (26–29).
Changes in Tc reflect changes in elongation rate and termina-
tion. This seems to be true in as far as the specific radioactivity
of the precursor does not change over the 2-min period (28, 29).
In our experiments, the total acid-soluble valine specific radio-
activity was determined at each experimental time. The results
were 368.7 6 17.8 cpm for control rats and 356.7 6 19.11 cpm
for CH-treated rats (mean 6 S.E. of 10 animals), with no
significant changes at different times between 30 and 120 s.
These small variations were not statistically significant as
determined by ANOVA, followed by Tukey’s test.
In our experiments, Tc was obtained directly from the slope
of a plot of Pn/Pt versus time. Fig. 1 summarizes the values of
hepatic Pn/Pt at different times after injection of the tracer in
control (Fig. 1a) and CH-treated rats (Fig. 1b). The value Pn/Pt
was reduced from 50 to 25% in 60 s in the normal liver and in
101 s in the CH-treated one (see legend to Fig. 1).
Effect of CH Treatment on Hepatic Polyribosomal Profiles—
The polypeptide chain completion time is an expression of the
rate of the peptide chain elongation and termination steps. It is
independent of the number of ribosomes engaged in the process
and it should not be affected by variations in the initiation step
(28). However, in order to determine whether the effect ob-
served by CH treatment was accompanied by a significant
effect of the initiation step, the ribosomal state of aggregation
was determined by studying the hepatic polyribosomal profiles
in control and CH-treated rats.
As shown in Fig. 2, CH treatment increased the ribosomal
state of aggregation (Fig. 2b) with respect to controls (Fig. 2a).
An increase of 69% in the ratio polysomes/monomers was ob-
served in CH-treated rats (see legend to Fig. 2). These results
indicate that CH treatment acts preferentially on the elonga-
tion or termination step, or both.
Effect of CH Treatment on the Amount of Absolute and Active
EF-2 and on Its Oxidation State in Rat Liver—We have meas-
ured the total content of EF-2 using the polyclonal antibody
against EF-2. As can be seen in Table II, there is no change in
the total amount of EF-2 in CH-treated rat with respect to
control rats. Moreover, we have used the diphtheria toxin-
mediated 1:1 stoichiometric ADP-ribosylation of the diphth-
amide residue of EF-2 in liver extract in the presence of radio-
active NAD, to determine the amount ADP-ribosylatable EF-2
TABLE I
Effect of CH treatment on MDA level and carbonyl groups content of
proteins and EF-2
MDA was determined by thiobarbituric acid reactive substances.
Carbonyl groups in total protein were determined using radioactive
sodium borohydride. See “Materials and Methods” for details. Numbers
in parentheses indicate number of rats in the group.
Control CH
MDA (nmol/mg protein)
10,000 3 g supernatant 22.4 6 2.3 53.2 6 18.0a,b
(5) (5)
Microsomes 28.8 6 10.5 97.4 6 9.6a,c
(5) (5)
CO content in proteins (nmol
CO group/mg protein)
10,000 3 g supernatant 155.2 6 8.1 249.0 6 10.7a,d
(5) (5)
Microsomes 408.5 6 105 831.9 6 37.8a,e
(5) (5)
a Significantly different from level in control rats (multifactor
ANOVA followed by Tukey’s test, p , 0.05).
b F 5 32.43, p 5 0.0047.
c F 5 17.36, p 5 0.0141.
d F 5 35.4, p 5 0.0095.
e F 5 14.18, p 5 0.0197.
FIG. 1. Effect of CH on the rate of decay of the ratio between
the radioactivity incorporated into hepatic nascent peptides
and the radioactivity incorporated into hepatic total peptides
(Pn/Pt) in control (a) and CH-treated rats (b). Each point repre-
sents the mean 6 S.E. of four rats. Tc (seconds) was obtained from the
slope of the plot (see “Materials and Methods” for details). Tc in control,
60 s; Tc in CH-treated rats, 101 s.
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and, hence, of active EF-2 (31, 32). Our results show that the
amounts of ADP-ribosylatable EF-2 are reduced significantly
(32% reduction) during the treatment of CH as measured by
the content of diphtheria toxin-mediated ADP-ribosylatable
EF-2 (Table II).
CH treatment also modified the oxidation state of EF-2. For
this experiment a polyclonal antibody against EF-2 was used.
The carbonyl content of immunoprecipitated EF-2 from rats
treated with CH was significantly increased (2-fold) (Table I),
which suggests that EF-2 is highly affected by oxidative
damage.
In Vitro Effect of CH on EF-2 Present in Control Liver Ho-
mogenate—A control experiment was done to study the effect of
CH on control EF-2 present in liver homogenates. As shown in
Fig. 3, pretreatment with CH resulted in a 45% decreased
incorporation of [14C]ADP-ribose, which suggests that CH spe-
cifically produced a decrease in the amount of active EF-2. In
addition, treatment of rat liver homogenates with CH produced
a 1.8-fold increase in the carbonyl group content of EF-2.
DISCUSSION
The present study was undertaken to elucidate the mecha-
nism of protein synthesis inhibition produced by the oxidative
stress mediated by CH. CH is an oxidant that has been used as
a model compound to assess the effect of oxidative stress on
various biological systems (17–22). The evidence that CH pro-
duces oxidative damage is that treatment with CH resulted in
an increase of MDA, as measured by thiobarbituric acid-reac-
tive substances (Table I). This result agrees with previous
reports (34, 35). In addition, CH produced oxidative modifica-
tion of proteins (Table I) as the carbonyl groups content
increased.
Besides the damaging effect of CH on biological molecules, it
has been reported that CH inhibits protein synthesis in cell
cultures (14, 15). These reports were based on the incorporation
of radioactive amino acid into proteins. The application of such
a method “in vivo” is more limited because of the lack of reliable
information on the specific activity of the precursor pool in vivo
(36–39). In order to overcome this limitation when studying the
effect of CH on the various steps of protein synthesis, we have
determined the average polypeptide chain assembly time along
with the study of the polyribosomal profiles. The time constant
for assembly and release of polypeptide chains in rat liver in
vivo has been determined by a technique described previously
(26–29), which is independent of most sources of variation and
error in amino acid incorporation experiments. Valine was
selected as the amino acid for measurement of protein synthe-
sis because of the poor capacity of the hepatic cells to metabo-
lize it (40). Our results show that the time required to reduce
Pn/Pt from 50 to 25% was 1.7-fold higher in CH-treated rats
(Fig. 1). This increase in Tc would cause a 40% drop in protein
production per unit time if all other factors were equal. These
results indicate that CH treatment affects the elongation
and/or termination step.
The possible involvement of initiation step has been ad-
dressed by studying the ribosomal pattern of aggregation. Un-
der normal conditions, initiation and elongation are synchro-
nized in such a way that any perturbation in only one of them
would produce variations in the ribosomal pattern of aggrega-
tion (28, 29). Thus, inhibition of peptide chain initiation would
produce an accumulation of monomeric ribosomes and polyri-
bosomal breakdown (28). When only the elongation process is
inhibited (or it is inhibited to a greater extent than initiation),
FIG. 2. Sucrose gradient analysis of ribosome preparations
from livers of control (a) and CH-treated (b) rats. The polyriboso-
mal profiles were obtained as described under “Materials andMethods.”
The ratio polysomes/monomers was calculated as described under “Ma-
terials and Methods.” This ratio was 17.25 6 2.9 in control rats and
29.30 6 2.8* in CH-treated rats. These results are means 6 S.E. of five
animals. *, significantly different from level in control rats (multifactor
ANOVA followed by Tukey’s test, p , 0.05; F 5 13.37, p 5 0.0106).
TABLE II
Effect of CH treatment on the amount of total and active EF-2 and on
its oxidation state
Total amount of EF-2 was measured by ELISA. Active amount of
EF-2 was measured using radioactive NAD plus DT. Carbonyl groups in
EF-2 were determined using radioactive sodium borohydride. Results
are means 6 S.E. of 4–5 rats. See “Materials and Methods” for details.
Control rats CH-treated rats
Amount of total EF-2
(absorbance @ 405 nm)
0.173 6 0.010 0.197 6 0.016
ADP-ribosylatable EF-2
(pmol/mg protein)
13.54 6 1.48 8.92 6 1.03a,b
CO content in EF-2 (nmol CO
group/mg protein)
3.58 6 0.53 5.60 6 0.39a,c
a Significantly different from level in control rats (multifactor
ANOVA, Tukey’s test, p , 0.05).
b F 5 6.96, p 5 0.0386.
c F 5 85.46, p 5 0.0008.
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an increased proportion of polyribosomes and a depletion of the
monomeric ribosome pool is obtained (28). No change of the
ribosomal aggregation patterns would be found if elongation
and initiation are completely inhibited. In our case, the polyri-
bosomes displayed a higher state of aggregation in CH-treated
rat liver (Fig. 2). These results indicate that changes in peptide
chain elongation may be an important mechanism in altering
the rate of protein synthesis by CH. The possibility that the
chain release mechanism may be rate-limiting (and hence,
modulated by CH) cannot be excluded by the model used for
determination of Tc.
EF-2 is an essential factor involved in the regulation of the
elongation step of protein synthesis (41–43). In order to study
the possible implication of EF-2 in causing the decline of elon-
gation step by CH, we studied the effect of CH treatment on the
amount of total EF-2 in liver of control and CH-treated rats. No
change in total EF-2 was observed in CH-treated rat with
respect to control rats (Table II). This result indicates that the
observed decline in protein synthesis rate is not due to a de-
crease in the steady-state level of EF-2, and suggests that
changes in protein synthesis and the elongation step could be
due to post-translational modification of EF-2. In order to test
this possibility, we have studied the amount of active EF-2 and
its oxidation state.
EF-2, which catalyzes the translocation of peptidyl-tRNA
from the site A to the site P of the ribosome, contains an
unusual amino acid named diphthamide, whose importance for
the function of EF-2 has been reported (43, 44). The diphth-
amide residue is specifically ADP-ribosylated by fragment A of
DT, which catalyzes the transfer of ADP-ribose from NAD, thus
inactivating it (42, 44). The level of ADP-ribosylatable EF-2,
which has been used as an indirect measurement of the amount
of active EF-2 in extracts (31, 32), can be determined by using
the assay of ribosylation of the diphthamide mediated by DT.
Although the diphthamide residue as such is not essential for
the function of EF-2 in protein synthesis, it has been suggested
that the role of this residue is to allow the cell to regulate the
rate of elongation by ADP-ribosylation (43, 45–51).
A statistically significant reduction of the amount of ADP-
ribosylatable EF-2 (32% reduction) is observed during the
treatment of CH (Table II). At the same time, our results show
that hepatic EF-2 from rats treated with CH was oxidatively
damaged, as indicated by the increase in the carbonyl groups
content (Table II). Although the oxidative modification may
occur in a region of the EF-2 remote from the catalytic site, this
result does prove that EF-2 is oxidatively modified by CH
treatment, although it does not prove that EF-2 is inactivated.
Taken together, these results show that the inhibition of
protein synthesis by CH could be produced by changes in the
elongation step and that this decline in the elongation step
could be due to the post-translational modifications of EF-2,
which result in an increased oxidative damage and less active
form of EF-2.
In order to relate the post-translational modifications found
in vivo with the oxidative stress damage, a control experiment
was carried out to test the in vitro effect of CH on control EF-2
(Fig. 3). The result of this experiment showed that CH also
affects the level of ribosylatable control EF-2 and carbonyl
groups content in a similar manner to that found in vivo.
The reason for the decrease in the amount of active EF-2
observed in CH-treated rats can be due to various factors: 1) a
chemical modification of diphthamide by oxyradicals, which
would abolish the DT-mediated ribosylation; 2) an activation of
endogenous ribosylation of the diphthamide by ribosyltrans-
ferases. This ribosylation seems to regulate the rate of protein
synthesis as part of normal cellular metabolism (46–51) and
could be activated by oxidative stress. 3) EF-2 amino acid
modification by oxidation: EF-2 has a histidine, which is essen-
tial for its activity (44). Because histidine is one of the amino
acid residues most susceptible to oxidative damage (52–53), it
is possible that free radicals produced by CH could affect the
activity of EF-2 through a mechanism involving histidine inac-
tivation by oxidation. 4) conformational changes in EF-2 in-
duced by oxidative modification mediated by free radicals.
The second possibility is not unreasonable considering a
previous report showing that oxidative stress activates protein
ADP-ribosylation in the catabolism of one major route of pyri-
dine nucleotide (54). If this is the case, ADP-ribosylation acti-
vated by CH could be responsible for the decline of the elonga-
tion step, as this reaction is a nonreversible phenomenon.
Although the ADP-ribosylation does not distinguish between
active and inactive EF-2 for reasons other than ADP-ribosyla-
tion, such as phosphorylation, it has been suggested by Bod-
ley’s group (43, 55–57) that diphthamide residue serves as the
recognition element on EF-2 for the calmodulin-dependent pro-
tein kinase. Therefore, a lower level of diphthamide could also
affect the regulation of the activity of EF-2 by phosphorylation.
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